PRTG | Jotup

CloudFabrix to demonstrate its Unified Network Observability and Automation solution, now also available on Splunk, at CiscoLive 24

Retrieved on:

金曜日, 5月 31, 2024

Technology, Networks, Robotics, Data Management, Cloud, LLDP, VMware, Ecosystem, OSPF, SDWAN, RAG, LLM, RDA, Meraki, Infrastructure, Macaw, Multimedia, Radar, BGP, Intelligence, CLI, Security, Multi, Telemetry, ThousandEyes, Platform, RDAF, PRTG, SNMP, GRPC, Data, API, Network, Challenger, AI, Service, IBM Consulting, EMA, Root cause analysis, CDP, Financial services, Performance management, Mobile phone

The stakes for an unified network observability and automation solution have never been higher, which becomes the central single pane of Ops across observability, security and networking siloed domains.

Key Points:

The stakes for an unified network observability and automation solution have never been higher, which becomes the central single pane of Ops across observability, security and networking siloed domains.
CloudFabrix’s Unified Network Observability and Automation solution specifically addresses these challenges.
“Our clients will benefit from the CloudFabrix Unified Network Observability and Automation solution.
Much of the CloudFabrix Unified Network Observability offering is built on its Robotic Data Automation Fabric (RDAF), which creates rich pipelines anywhere in the infrastructure.” said Ron Williams, Principal analyst Gigaom.

Paessler AG's Breanne Smiley and Danielle Travis Recognized as 2024 CRN® Women of the Channel

Retrieved on:

月曜日, 5月 13, 2024

Organization, The Channel Company, Channel, Woman, US West, PRTG

CHICAGO, May 13, 2024 /PRNewswire/ -- Paessler AG , the monitoring experts, announced today that CRN®, a brand of The Channel Company , has recognized two of its North American channel leaders, Breanne Smiley and Danielle Travis, on its 2024 Women of the Channel list.

Key Points:

CHICAGO, May 13, 2024 /PRNewswire/ -- Paessler AG , the monitoring experts, announced today that CRN®, a brand of The Channel Company , has recognized two of its North American channel leaders, Breanne Smiley and Danielle Travis, on its 2024 Women of the Channel list.
With this recognition, CRN® honors these women leaders for their unwavering dedication and commitment to furthering channel excellence.
Danielle Travis, manager of inside sales, Americas, advanced Paessler's channel business by streamlining multiple processes, resulting in increased efficiency that enabled the Paessler channel team to better serve partners and distributors.
The 2024 Women of the Channel list will be featured in the June issue of CRN® Magazine, with online coverage starting May 13 at www.CRN.com/WOTC .

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

Retrieved on:

金曜日, 4月 12, 2024

PRTG, Sale, Wind, Adenosine, Portage, Disclosure, Pharmaceutical industry

WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.

Key Points:

WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.
There can be no assurance that the evaluation of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms.
If the Company is unable to complete a transaction, it may be required to seek a restructuring or company wind down.
There is no set timetable for this evaluation and Portage does not intend to disclose developments with respect to this evaluation unless and until it determines that further disclosure is appropriate or legally required.

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Retrieved on:

火曜日, 3月 26, 2024

Immunotherapy, Society, Therapy, ASCO, SITC, PRTG, Intensity, Annual general meeting, Pharmaceutical industry

WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ: INTS).

Key Points:

WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ: INTS).
Portage was an early INTS investor and during the past few months, Portage has been able to monetize its equity holdings in INTS and bring in proceeds, net of related expenses, totaling $2.8M of non-dilutive funding.
The Company will use the proceeds to further fund its PORT-6 Phase 1a portion of the ADPORT-601 trial.
“We are excited with the potential of the Company’s adenosine platform and are focusing our efforts on advancing its ADPORT-201 Phase 1a/1b clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor) in selected solid tumors.”

Paessler AG Earns Premier 5-Star Rating in 2024 CRN® Partner Program Guide

Retrieved on:

月曜日, 3月 25, 2024

Certification, Award, Growth, Communication, Education, CRN, OT, Marketing, PRTG, The Channel Company

CHICAGO, March 25, 2024 /PRNewswire/ -- CRN®, a brand of The Channel Company , has recognized Paessler AG , the monitoring experts, with a prestigious 5-Star Award in its 2024 Partner Program Guide.

Key Points:

CHICAGO, March 25, 2024 /PRNewswire/ -- CRN®, a brand of The Channel Company , has recognized Paessler AG , the monitoring experts, with a prestigious 5-Star Award in its 2024 Partner Program Guide.
For the 2024 Partner Program Guide, CRN evaluated vendors based on program requirements and offerings such as partner training and education, pre- and post-sales support, marketing programs and resources, technical support, and communication.
"We are honored to be recognized with a 5-Star Award in CRN's 2024 Partners Program Guide," says Helmut Binder, CEO, Paessler AG.
With CRN's 2024 Partner Program Guide, solution providers can access deep insights into the unique strengths of each partner program and vendors who demonstrate dedication to their partner community."

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Retrieved on:

水曜日, 2月 28, 2024

WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023.

Key Points:

WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023.
R&D costs increased slightly by approximately $0.1 million, or approximately 1%, from approximately $2.7 million in the Fiscal 2023 Quarter, to approximately $2.8 million in the Fiscal 2024 Quarter.
G&A expenses decreased by approximately $0.7 million, or approximately 35%, from approximately $2.0 million in the Fiscal 2023 Quarter, to approximately $1.3 million in the Fiscal 2024 Quarter.
The Company’s other pre-tax items of income and expense were substantially non-cash in nature and aggregated to approximately $44.9 million net expense in the Fiscal 2024 Quarter, compared to approximately $0.6 million net expense during the Fiscal 2023 Quarter.

Paessler AG's Mike Gonzalez and Peter Campisi Recognized as 2024 CRN® Channel Chiefs

Retrieved on:

月曜日, 2月 5, 2024

Growth, Editing, MSP, PRTG, Industrial, CRN, Development, Acquisition, The Channel Company, Campisi, Management

CHICAGO, Feb. 5, 2024 /PRNewswire/ -- Paessler AG , the monitoring experts, announced today that CRN®, a brand of The Channel Company , has recognized two of its North American channel leaders, Mike Gonzalez and Peter Campisi, on its 2024 Channel Chiefs list.

Key Points:

CHICAGO, Feb. 5, 2024 /PRNewswire/ -- Paessler AG , the monitoring experts, announced today that CRN®, a brand of The Channel Company , has recognized two of its North American channel leaders, Mike Gonzalez and Peter Campisi, on its 2024 Channel Chiefs list.
Each year, the prestigious CRN® Channel Chiefs list recognizes the IT vendor and distribution executives who are driving strategy and setting the channel agenda for their companies.
2024 is the second consecutive year that Gonzalez has been named to the list, and the third for Campisi, for their impact on the channel.
The Channel Company is pleased to acknowledge these prominent channel leaders and looks forward to chronicling their achievements throughout the year."

Portage Biotech Reports Business and Strategic Update

Retrieved on:

木曜日, 1月 4, 2024

PRTG, Adenosine, Drug development, Merck & Co., Disclosure, Merck, Patient, Therapy, Pembrolizumab, Pharmaceutical industry

The phase 1a dose escalation portion of the trial is enrolling quickly and there have been no safety signals of concern at the doses evaluated to date.

Key Points:

The phase 1a dose escalation portion of the trial is enrolling quickly and there have been no safety signals of concern at the doses evaluated to date.
The company looks forward to presenting data from this portion of the trial at a conference later this year.
There is still much to learn about how to develop therapeutics for this target,” remarked Dr. Walters.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Retrieved on:

火曜日, 11月 28, 2023

WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023.

Key Points:

WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023.
“The Company is focused on developing its two lead clinical programs and maximizing its resources given market conditions.
Portage completed a $6 million financing in October 2023 for continued clinical development, general corporate and working capital purposes.
R&D costs increased by approximately $2.7 million to approximately $4.2 million, or approximately 180%, for the Fiscal 2024 Quarter from approximately $1.5 million in the Fiscal 2023 Quarter.

Paessler AG's PRTG OPC UA Server wins New Equipment Digest's Innovation Awards in Software & Computer Category

Retrieved on:

火曜日, 11月 28, 2023

OPC, Glass, Software, NED, OT, Element, Paessler PRTG, PRTG, Computer, OPC UA, Architecture, Video game, Online shopping

CHICAGO, Nov. 28, 2023 /PRNewswire/ -- Paessler AG, the creator of technology monitoring software PRTG, has been selected as the New Equipment Digest (NED) Innovation Awards winner in the Software & Computer category for PRTG OPC UA Server, its product extension created specifically for the industrial/manufacturing industry.

Key Points:

PRTG OPC UA Server is one of 15 products selected for prestigious industrial technology, tools and equipment award
CHICAGO, Nov. 28, 2023 /PRNewswire/ -- Paessler AG , the creator of technology monitoring software PRTG , has been selected as the New Equipment Digest (NED) Innovation Awards winner in the Software & Computer category for PRTG OPC UA Server , its product extension created specifically for the industrial/manufacturing industry.
Paessler's PRTG OPC UA Server was one of 15 products selected for this year's awards.
"We are thrilled that New Equipment Digest readers voted for PRTG OPC UA Server to win the NED Innovation Award in the Software & Computer category," said David Montoya, Paessler AG's Global IoT Business Development Manager.
For more information about PRTG OPC UA Server, or other ways that PRTG helps industrial operations, visit https://www.paessler.com/prtg/extensions/prtg-opc-ua-server .